Forbion Capital Partners Investor
Forbion Capital Partners is a venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion's investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed €400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.
Invests into
Investors
Number Of Exists:
37
Funding Status:
private
Founded Date:
2006-01-01
Employee Number:
11-50
Investor Type:
Venture Funds
Industry:
RNA & Oligonucleotide Medicines
Headquarters:
Naarden,Noord-Holland,The Netherlands,Europe